ArriVent BioPharma upsizes proposed IPO to $150M from $100M - Seeking Alpha

Retrieved on: 2024-01-22 23:26:20

Tags for this article:

Click the tags to see associated articles and topics

ArriVent BioPharma upsizes proposed IPO to $150M from $100M - Seeking Alpha. View article details on HISWAI: https://seekingalpha.com/news/4057168-arrivent-biopharma-upsizes-proposed-ipo-to-150m-from-100m%3Fsource%3Dcontent_type%253Areact%257Cfirst_level_url%253Amarket-news%257Csection_asset%253Amain

Summary

ArriVent Biopharma, aiming to treat non-small-cell lung cancer targeting EGFR mutations, increased its IPO goal to $150M, advancing its drug candidate furnmonertinib in Phase 3 trials.

Article found on: seekingalpha.com

View Original Article